Biomea Fusion Inc (NASDAQ: BMEA)’s stock price has decreased by -31.49 compared to its previous closing price of 2.90. However, the company has seen a -20.53% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-18 that Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I study initiation in obese, otherwise healthy volunteers anticipated late 2025 REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company’s investigational, next-generation oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA).
Is It Worth Investing in Biomea Fusion Inc (NASDAQ: BMEA) Right Now?
Additionally, the 36-month beta value for BMEA is -0.21. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for BMEA is 32.80M and currently, short sellers hold a 31.60% ratio of that float. The average trading volume of BMEA on June 18, 2025 was 1.94M shares.
BMEA’s Market Performance
BMEA stock saw an increase of -20.53% in the past week, with a monthly gain of 31.57% and a quarterly increase of -27.23%. The volatility ratio for the week is 9.62%, and the volatility levels for the last 30 days are 12.70% for Biomea Fusion Inc (BMEA). The simple moving average for the last 20 days is -5.63% for BMEA stock, with a simple moving average of -59.95% for the last 200 days.
Analysts’ Opinion of BMEA
Many brokerage firms have already submitted their reports for BMEA stocks, with Piper Sandler repeating the rating for BMEA by listing it as a “Overweight.” The predicted price for BMEA in the upcoming period, according to Piper Sandler is $7 based on the research report published on June 03, 2025 of the current year 2025.
Edward Jones, on the other hand, stated in their research note that they expect to see BMEA reach a price target of $128. The rating they have provided for BMEA stocks is “Buy” according to the report published on October 09th, 2024.
Truist gave a rating of “Buy” to BMEA, setting the target price at $54 in the report published on September 27th of the previous year.
BMEA Trading at 3.09% from the 50-Day Moving Average
After a stumble in the market that brought BMEA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.80% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMEA starting from Hitchcock Michael J.M., who purchase 10,000 shares at the price of $10.06 back on Sep 30 ’24. After this action, Hitchcock Michael J.M. now owns 15,000 shares of Biomea Fusion Inc, valued at $100,600 using the latest closing price.
Stock Fundamentals for BMEA
Current profitability levels for the company are sitting at:
- -108.79 for the present operating margin
- 0.34 for the gross margin
The net margin for Biomea Fusion Inc stands at -81.45. The total capital return value is set at -3.77. Equity return is now at value -156.81, with -115.08 for asset returns.
Based on Biomea Fusion Inc (BMEA), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -14.32.
Currently, EBITDA for the company is -136.68 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 38.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
In conclusion, Biomea Fusion Inc (BMEA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
